Compare Abbott Laboratories (ABT) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Skyworks Solutions Inc — how do they compare? Abbott Laboratories trades at $110.72 (market cap $187.95B), while Skyworks Solutions Inc trades at $68.52 (market cap $10.28B). The key difference: Abbott Laboratories is far larger — about 18.3× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| ABT | SWKS | |
|---|---|---|
Market Cap | $187.95B | $10.28B |
Sector | Health | Technology |
52-Week High | $136.62 | $83.40 |
52-Week Low | $82.57 | $52.50 |
Enterprise Value | $214.96B | $10.16B |
Dividend Yield | 2.32% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Skyworks Solutions (SWKS) trades at $68.17, down 0.9% today, with a bullish technical signal from moving averages and recent earnings beats in Q2 2026. The stock shows strong institutional buying interest and a 58% analyst buy rating, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. The pending Qorvo combination and AI data center growth present strategic opportunities, but profitability margins have compressed, and a legal investigation adds near-term uncertainty.
The outlook is cautiously optimistic, supported by earnings consistency and diversification into automotive and AI markets, but investors face risks from integration execution, margin pressure, and regulatory scrutiny. The consensus price target of $66 suggests limited upside, requiring careful monitoring of merger progress and quarterly performance against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
